Tag:

Biotech IPO

Latest Headlines

Latest Headlines

Biotech fledglings crowd into a still-sizzling market for IPOs

Boulder, CO-based Nivalis Therapeutics rode the hot market for biotech IPOs to a $77 million windfall, banking on a very early-stage cystic fibrosis effort that's looking to ride on the coattails of a new combo therapy from Vertex.

Pioneering microbiome upstart Seres Therapeutics targets a $100M IPO

Microbiome pioneer Seres Therapeutics is taking its promising lead therapy and the high expectations for an emerging field in biotech and heading to Wall Street, where it hopes to raise $100 million in an IPO that is likely to provide another litmus test of investors' appetite for new drug technologies.

Kite CEO Arie Belldegrun fills a prescription for tax bite

Death and taxes may both be unavoidable, but Kite Pharma CEO Arie Belldegrun at least knows how to limit the pain on part of that equation.

High-flying immuno-oncology player Adaptimmune pitches $150M IPO

Adaptimmune Therapeutics has become one of the brightest hopes in the U.K. biotech scene, scoring a $350 million collaboration pact with GlaxoSmithKline and a whopping $104 million venture round. Now Adaptimmune--a 2014 Fierce 15 company--will see if it can keep the hot streak rolling with a $150 million IPO pitch.

Flagship banks $537M to back the next batch of biotechs

Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.

Summit pulls off a downsized IPO for its DMD drug

The U.K.'s Summit Therapeutics is elbowing its way into the race to treat Duchenne muscular dystrophy, pulling off a $34 million U.S. IPO to fund its research.

Cerenis files for IPO to resurrect clinical-phase cholesterol drug

Cerenis Therapeutics has filed the paperwork for an IPO in Europe as it looks to bounce back from the failure of a Phase II trial of its HDL-like drug.

Ex-Elan execs target €325M IPO for life science fund

Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.

PRA joins the CRO in-crowd with a $306M IPO

CRO conglomerate PRA Health Sciences pulled off a $306 million IPO, joining the growing list of Big Pharma contractors cashing in on Wall Street after years under private equity stewardship.